Related Experiment Video

Updated: Jul 10, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

Singin' the blues: the downside of hepatitis C virus treatment

Edmund J Bini

    The American Journal of Gastroenterology
    |October 26, 2007
    PubMed

    Insights

    Hepatitis C virus (HCV) patients with stable psychiatric conditions can be safely treated with interferon and ribavirin. This approach, supported by new research, offers a viable treatment option for many.

    Area of Science:

    • Hepatology
    • Psychiatry
    • Infectious Diseases

    Background:

    • Interferon-based therapies for Hepatitis C virus (HCV) infection can cause neuropsychiatric side effects.
    • Poorly controlled psychiatric disease is a strict contraindication for interferon and ribavirin treatment.
    • The safety and efficacy of treating HCV in patients with stable psychiatric conditions remain a subject of debate.

    Discussion:

    • Emerging data suggest that HCV-infected patients with stable psychiatric disease can tolerate interferon and ribavirin therapy.
    • A study by Jakiche and colleagues provides evidence supporting the safety of this treatment approach.
    • Careful patient selection and monitoring are crucial for managing potential neuropsychiatric side effects.

    Key Insights:

    • HCV treatment with interferon and ribavirin may be safe for patients with stable psychiatric disease.
    • Multidisciplinary collaboration between gastroenterologists and mental health professionals is essential.
    • This evidence expands treatment options for a significant patient population.

    Outlook:

    • Further research is needed to fully understand the long-term outcomes and optimal management strategies.
    • Developing standardized protocols for managing psychiatric comorbidities during HCV treatment is important.
    • Increased collaboration can improve access to curative HCV therapies for patients with psychiatric conditions.

    More Related Videos

    Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice07:25

    Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

    Published on: September 25, 2019

    Related Concept Videos

    Hepatitis01:25

    Hepatitis

    Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
    Viral Hepatitis I: Introduction01:28

    Viral Hepatitis I: Introduction

    Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
    Diseases of the Liver and Gallbladder01:26

    Diseases of the Liver and Gallbladder

    Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
    Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
    Cirrhosis II: Pathophysiology01:24

    Cirrhosis II: Pathophysiology

    Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
    Cirrhosis I: Introduction01:23

    Cirrhosis I: Introduction

    Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
    Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

    Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

    Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...